Lundbeck

The impact of brain disorders is escalating. It is estimated that brain disorders directly affect half the world’s population, and the effects are felt throughout society. Every day we go to work to address high unmet medical needs for people living with brain disorders. Patients who have few or no treatments available. Through cutting-edge science and strong partnerships, we develop and market some of the world’s leading treatments, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. Our most important contribution is easing the burden of the millions of people living with brain disorders. Whether it is migraine, depression, or other brain disorders, patients, their carers, and society as a whole depend on us. At Lundbeck, we are - Advancing brain health. Transforming lives. #AdvancingBrainHealth #FocusedInnovator

In 2021, brain conditions caused more disability-adjusted life-years (522 million) than other widely acknowledged health threats such as cancer or cardiovascular disease. In particular, neurological disorders are the leading source of disability-adjusted life-years (DALYs) - a measure of overall disease burden, expressed as the number of years lost due to ill-health, disability, or early death. These numbers show that the brain health challenge is real. And our domain expertise in brain health provides us with the strongest possible foundation for discovering and developing new treatments in this increasingly important area. For over 70 years, our research and innovations have aimed to improve the quality of life for those affected by psychiatric and neurological conditions and we will continue for the years to come. #AdvancingBrainHealth #Neurology #DiseaseAwareness (Source: IHME, Brain Health Atlas)

Uniting minds innovating mental health solutions at Tour de Health'24 Tour de Health is a high-level international dialogue-based conference that aims to engage international delegates from 13 countries in showcasing Danish good practices in multi-stakeholder collaborations. This year, Lundbeck had the honor of hosting an inspiring event as part of the conference. The gathering brought together experts, practitioners, and advocates to discuss pressing issues in mental health care, fostering collaboration and dialogue among global stakeholders while co-creating context-based approaches to address current healthcare challenges. The event featured powerful stories from two patients who shared their personal experiences with mental illness. One patient highlighted how virtual reality, a solution which was presented by Simon Lajboschitz, Co-Founder & CEO of Khora Virtual Reality, helped combat the voices in her head. Simon delivered a compelling presentation on this mental health solution, which is making a real difference for patients. Carlo V. Andersen, Head of the Danish Ministry of the Interior and Health, provided valuable insights into the Danish 10-year Psychiatry Plan, outlining the government’s commitment to improving health services. Karin Hamberg, Chief Medical Officer of Lundbeck, introduced the Danish Lighthouse Initiative, showcasing how partnerships can drive innovation in mental healthcare. Thomas L. Binzer from the Center for Digital Psychiatry in the Region of Southern Denmark explored the landscape of digital psychiatry and the need for innovative solutions to meet the growing demand for mental health services. The event concluded with an engaging debate moderated by Dr. Ruma Bhargava, Global Lead Mental Health at the World Economic Forum. Panelists, including Carlo V. Andersen, Frank Bellivier from the Ministry for Labour, Health and Solidarity in France, Karin Hamberg, and Thomas L. Binzer, discussed how multistakeholder collaboration can support tackling the rising rates of mental illness. Thank you to everyone who participated and contributed to this important discussion!

Meet us at the MDS congress in Philadelphia this weekend!   Lundbeck is proud to present study findings at the International Congress of Parkinson’s Disease and Movement Disorders (MDS Congress) in Philadelphia, USA this weekend.   These advancements underscore our commitment to addressing the unmet needs of MSA patients through rigorous research and innovation. We remain dedicated to transforming the lives of those affected by MSA.   Join us for our poster sessions or listen to our presentations to learn more about these exciting developments and discuss how we can work together to advance MSA research and treatment.   #AdvancingBrainHealth #MSA #MDSCongress 

We are excited to announce that Lundbeck has partnered with Iambic Therapeutics, a US-based clinical-stage biotech company, to leverage their AI-powered drug discovery platform. This collaboration aims to accelerate our research and innovation in developing treatments for neurological diseases, focusing on a small molecule therapeutic for migraine. This partnership aligns perfectly with our strategy of being a focused innovator in brain health, enhancing our ability to advance brain health through innovative treatments.   “Iambic’s state-of-the-art platform - including the NeuralPLexer protein-ligand structure prediction technology - will accelerate the generation of novel candidates with a higher probability of success at reaching our patients,” says Tarek Samad, SVP and Global Head of Research, Corporate Patents & Trademarks at Lundbeck. “The pace at which Iambic can both design molecules in silico and then test them in the laboratory has the potential to unlock compelling neurology targets that have eluded traditional drug discovery methods.”   This partnership reflects Lundbeck’s strong commitment to innovation across R&D. Merging the power of generative AI with expertise in developing drug candidates for brain diseases aims to significantly enhance the probability of success and reduce discovery timelines for novel therapeutics.   Click here to read the full press release: https://lnkd.in/eYRgtmmx

In this insightful blog, Johan Luthman, Executive Vice President, Head of R&D at Lundbeck discusses the complexities of defining unmet medical needs in drug development. He highlights the challenges of creating unbiased criteria that equally consider all disease areas, emphasizing the risk of neglecting chronic and debilitating neurological conditions like multiple system atrophy, Parkinson’s disease, or migraine. Luthman advocates for a holistic approach that integrates patient insights, scientific rationale, and societal value to ensure continued innovation and development of new treatments. Dive into the full article to explore how we can foster a sustainable ecosystem for medical advancements: https://lnkd.in/eEe_iEHv #AdvancingBrainHealth #UnmetMedicalNeeds

Last week we attended the Brain Days of the Science Summit 2024 in New York City, an important side-event of the United Nations General Assembly #UNGA79. Tarek Samad, our SVP, Global Head of Research, and colleagues from our global public affairs team represented Lundbeck with the purpose of advancing brain health through our focused innovator in neuroscience strategy. We supported our global partners Brain Capital Alliance and European Brain Council in bringing together funders, advocacy groups, investors, academia, and policymakers during the Brain Days. On Day 1, we focused on the brain economy, a new economic model anchored in brain capital and brain health as drivers of economic growth and human development. We had the privilege of joining a panel debate on the need for systemic investment in the brain economy and advocated for continued investment in innovative neuroscience. Over the next two days, discussions centered around the interconnection between neuroscience and society to support brain health across the life course. We emphasized how achieving a better understanding of the brain through innovation and neuroscience is crucial for improving brain health, which in turn benefits society. We feel inspired and are looking forward to continuing our work in advancing brain health and transforming lives through neuroscience. #BrainHealth #BrainDays #UNGA

Worldwide, over 55 million people have dementia. With the shift towards an older aged population, this number is estimated to almost double every 20 years, reaching 139 million in 2050. Alzheimer’s disease is the most common cause of dementia, accounting for 60-70% of dementia cases.* On this World Alzheimer’s Day, let’s unite to raise awareness and support for those affected. Together, we can make a difference by promoting early diagnosis, supporting caregivers, and advancing brain health through innovative neuroscience. Learn more about Alzheimer's disease on our website: https://lnkd.in/eNr5d3re #WorldAlzheimersDay #Dementia #DiseaseAwareness *(Sources: Alzheimer’s Disease International, WHO)

Even though this year's Migraine Awareness Day is over, it's important to remember that people still experience migraine every day. We need to continue to show our support and continue to change the conversation around migraine. Unsolicited advice, however well-meaning, is a phenomenon that needs to change. Join us in promoting understanding and empathy through better conversations. Explore how a better conversation works, and download and show the badge to be part of the change: migraineday.lundbeck #MigraineAwarenessDay #ChangeTheConversation

We’re proud to have Lundbeck US recognized as a Fortune Best Workplace in BioPharma 2024, in the small and medium-sized companies category! This prestigious award highlights our commitment to fostering an innovation-driven culture. It is a testament to the dedication of our US teams, who consistently exhibit curiosity, accountability, and adaptability in our mission to advance brain health and transform lives. In the last year, Great Place To Work US surveyed companies employing 8.2 million people in the U.S. and received 1.3 million survey responses. Of those, over 28,000 responses were received from employees at companies who were eligible for the 2024 Fortune Best Workplaces in Biotechnology & Pharmaceuticals list and this list is based on their feedback.  #BestWorkplace #AdvancingBrainHealth #TransformingLives #FocusedInnovator